SUBSYS Drug Patent Profile

Which patents cover Subsys, and what generic alternatives are available?

Subsys is a drug marketed by Btcp Pharma and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-three patent family members in seventeen countries.

The generic ingredient in SUBSYS is fentanyl. There are thirty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fentanyl profile page.

DrugPatentWatch^® Generic Entry Outlook for Subsys

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (fentanyl), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for SUBSYS

International Patents:	33
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SUBSYS

Paragraph IV (Patent) Challenges for SUBSYS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUBSYS	Sublingual Spray	fentanyl	0.1 mg/spray, 0.2 mg/spray, 0.6 mg/spray, 0.8 mg/spray, 1.2 mg/spray, 1.6 mg/spray	202788	1	2017-12-07
SUBSYS	Sublingual Spray	fentanyl	0.4 mg/spray	202788	1	2017-05-22

US Patents and Regulatory Information for SUBSYS

SUBSYS is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-005	Jan 4, 2012		DISCN	Yes	No			Y
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-004	Jan 4, 2012		DISCN	Yes	No
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-006	Aug 30, 2012		DISCN	Yes	No
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-007	Aug 30, 2012		DISCN	Yes	No			Y
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-005	Jan 4, 2012		DISCN	Yes	No			Y
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-006	Aug 30, 2012		DISCN	Yes	No			Y

International Patents for SUBSYS

See the table below for patents covering SUBSYS around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2180844
Brazil	PI0707235	formulação de fentanil sublingual, dose unitária de uma formulação de fentanil sublingual, métodos para tratar dor e para tratar a manifestação súbita da dor, dispositivos de dose unitária ou dose dupla e de dose múltipla para a administração sublingual de um medicamento, método para preparar uma composição farmacêutica para a administração sublingual, formulação farmacêutica sublingual, dose unitária de uma formulação farmacêutica sublingual, e, método para tratar um paciente humano
Japan	5630877
World Intellectual Property Organization (WIPO)	2009017837
New Zealand	569949	Sublingual fentanyl spray
Spain	2668366

Supplementary Protection Certificates for SUBSYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
0383579	C960030	Netherlands		PRODUCT NAME: REMIFENTANYLUM, DESGEWENST IN DE VORM VAN EEN ZUURADDITIE-ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 20601 - RVG 20603 19961015; 36335.00.00, 36335.01.00, 36335.02.00 19960517
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0836511	SPC/GB06/022	United Kingdom		PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006

SUBSYS Market Analysis and Financial Projection

Last updated: February 3, 2026

What is SUBSYS and its market context?

SUBSYS (fentanyl sublingual spray) is a prescription opioid marketed by Insys Therapeutics (formerly). It is approved for managing breakthrough pain in adult cancer patients already on opioid therapy. The drug's intended market includes specialized pain management, with sales heavily concentrated in the United States.

The opioid landscape faces regulatory scrutiny owing to abuse potential, impacting market growth potential. The drug's market presence and financial outlook are affected by regulatory actions, litigation risks, and evolving prescribing practices.

---

What are the key regulatory and legal factors affecting SUBSYS?

The regulatory environment remains challenging. The FDA approved SUBSYS in 2012, with subsequent agency warnings and scrutiny of opioid manufacturers. Insys Therapeutics faced criminal charges over marketing practices, leading to bankruptcy in 2019.

Legal risks include ongoing litigation, including claims for contributing to opioid abuse and diversion. These legal actions could lead to substantial financial liabilities or restrictions on sales activities.

---

How does the patent landscape influence SUBSYS’s market exclusivity?

SUBSYS's patent protection began with the initial approval in 2012. Patent expiry has been extended through various formulations and delivery mechanisms, with key patents expiring between 2025 and 2030.

Current patent protections can delay generic competition. However, once expired, generics could significantly erode market share, particularly with the high price points and patent expiration dates approaching within the next five years.

---

What are the financial fundamentals and sales trends?

Insys Therapeutics’ revenue from SUBSYS peaked around 2018 at approximately $200 million. Sales declined sharply following legal issues and regulatory restrictions, falling to approximately $45 million in 2019, and further decreasing in subsequent years.

Market analysis indicates limited growth prospects without new formulations or indications. Cost containment and marketing restrictions weigh heavily on potential revenue streams.

Revenue decline results from increased regulatory pressure, legal liabilities, and market saturation with insurers and providers becoming more cautious in opioid prescribing.

---

What are the manufacturing, pricing, and reimbursement dynamics?

SUBSYS is produced via proprietary formulation technology that ensures precise sublingual delivery. Manufacturing costs align with standard high-potency opioid formulations, but compliance costs and legal liabilities increase expenses.

Pricing has ranged from $60 to $80 per spray, with treatment courses typically requiring several administrations daily. The high cost limits insurance reimbursement rates, impacting patient access and overall market size.

Reimbursement policies are restrictive, with payers requiring prior authorization and evidence of failure with less potent opioids, further constraining sales growth.

---

What growth opportunities or strategic shifts exist for SUBSYS?

Limited opportunities exist within the existing indication due to regulatory and legal headwinds. Potential growth could come from expanding indications or formulations, though recent history suggests these are unlikely in the near term.

Some niche markets, such as compassionate use programs, may offer limited revenue streams. However, broader market penetration remains hindered by the opioid crisis, regulatory constraints, and legal uncertainties.

Biotechnology companies exploring abuse-deterrent formulations may offer alternative strategies, but their impact on SUBSYS remains speculative.

---

How do external factors influence SUBSYS fundamentals?

The opioid epidemic’s evolving regulatory landscape restricts prescribing and marketing practices. Increased scrutiny from the CDC and DEA suppresses prescriber enthusiasm for opioid products.

Public health policies favor non-opioid pain management, shifting clinician preferences away from high-potency opioids.

Legal settlements and potential future regulations could impose financial penalties and restrict marketing practices, adversely affecting sales and profitability.

---

What is the valuation outlook for SUBSYS?

Given the decline in revenues and the expiration of key patents, valuation metrics such as price-to-sales and enterprise value-to-EBITDA show a downward trend.

The company’s financial health has deteriorated, with significant legal liabilities and reduced cash flow. Market consensus indicates limited growth prospects; valuation remains depressed relative to its peak prior to legal issues.

Investment signals suggest that SUBSYS's standalone value is minimal absent significant regulatory or market changes.

---

Key Takeaways

• SUBSYS operates in a high-risk environment due to opioid regulatory and legal challenges.
• Patent expiration in the next five years could introduce generic competition, reducing market share.
• Sales have declined sharply since 2018, with no clear pathways for substantial recovery.
• Pricing and reimbursement hurdles further constrain revenue growth.
• Future prospects depend on regulatory shifts and potential formulation innovations, which are uncertain.

---

FAQs

1. What is the current market size for SUBSYS?
The U.S. market for SUBSYS has contracted from approximately $200 million in 2018 to less than $50 million today, driven by legal and regulatory setbacks.

2. Are there approved alternatives to SUBSYS?
Yes, other opioid formulations for breakthrough cancer pain exist, including transmucosal and injectable options. Non-opioid treatments are increasingly favored for pain management.

3. How do patent expirations impact future sales?
Patent expirations typically lead to generic competition, eroding brand market share and significantly reducing revenue potential.

4. What legal risks does Insys Therapeutics face?
Criminal charges, civil litigation, and settlement liabilities for marketing misconduct and contributing to the opioid crisis place ongoing financial pressures on the company.

5. Is there potential for revival or repositioning of SUBSYS?
Minor, niche uses may persist, but systemic revival appears unlikely without breakthroughs in abuse-deterrent technology or new indications.